Science: COVID-19 pandemic continues, but "hope drugs" may be exhausted

However, a recent report in Science suggests that there may be a shortage of this promising drug in the future, both in terms of reserves and supply chains: 10.1126/science.abd4447Stephen Schondelmeyer, director of drug research at the University of Minnesota's Twin Cities Institute of Management and Economics, said: "Even if this is an old drug that has been around for a long time, I think it's still premature to say that it's generally available." Now that hoarding and speculative procurement have begun, the resulting shortage of drugs is already evident"
desemin methods include oral and intravenous injections, which are more difficult to produce than intravenous drugs, as the entire production process needs to be performed under sterile conditions to prevent microorganisms from reducing their efficacy or causing discomfort in patientsaccording to a recent list of drugs in short supply by the American Association of Health System Pharmacists, intravenous cemissone is already in short supply in the United StatesAt the same time, the FDA has listed the drug as a "shortage", the NHS has included the drug in its standard of care for COVID-19, and the country has imposed restrictions on the export of dexamethasonecorresponds to the shortage of medicines to the problem of insufficient production supplyMost dexametison sons are produced by two Indian companies, Wockhardt and Cadilla HealthcareHowever, in an interview with the media on Wednesday, Habil F Khorakiwala, Chief Executive Officer of Wockhardt, said the supply available for export was "very limited"Although Khorakiwala claims that it has a "huge capacity" to produce oral disemiffon and venous semysone, Schondelmeyer doubts: "There are not many factories that have the capacity to produce sterile injections, let alone dexamethast, so I doubt their production capacity." Cadilla, another company, has been shut out by the FDA 83 times since 2004 because of product quality issues, and has received three warning letters from the FDA since 2015 about unsafe production processesIn response to the FDA's latest letter, Cadilla said it would not produce injectable drug products for the U.SmarketEmer Cooke, head of drug regulation sand and other health technologies at the, argues that dexamethasone must be purchased from quality-assured suppliers because of the "high risk of rogue manufacturers offering non-conforming or falsified options"While trusted drug manufacturers should be able to meet growing demand, if hoarding continues to grow, "there will be confusing demand signals and put scale expansion plans at risk".